Skip to main navigation Skip to search Skip to main content

NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma

  • Amanda Adler*
  • , Samuel Slayen
  • , Heather Stegenga
  • , Yelan Guo
  • , Richard Diaz
  • , Nicky J Welton
  • , Nigel Westwood
  • , Iolo Doull
  • , Charles Crawley
  • *Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)
192 Downloads (Pure)
Original languageEnglish
Pages (from-to)e92-e93
JournalLancet Respiratory Medicine
Volume10
Issue number10
Early online date18 Aug 2022
DOIs
Publication statusPublished - 1 Oct 2022

Research Groups and Themes

  • BrisTAG

Keywords

  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Humans
  • Ipilimumab/therapeutic use
  • Mesothelioma/drug therapy
  • Mesothelioma, Malignant/drug therapy
  • Nivolumab/therapeutic use
  • Pleural Neoplasms/drug therapy

Cite this